Tonix Pharmaceuticals Holding

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, licensing, acquiring, and developing drugs and biologics to treat and prevent human disease and alleviate suffering in the United States. It is developing TNX-102 SL, a tablet containing cyclobenzaprine that is Phase III clinical trial for the treatment of fibromyalgia; and that is in Phase III clinical trial for the treatment of posttraumatic stress disorder, as well as TNX-102 SL for the treatment of agitation in Alzheimer's disease and alcohol use disorder. The company is also developing TNX-1300, a recombinant protein enzyme, which is in Phase II clinical trial for the treatment of cocaine intoxication; TNX-1800, a vaccine for the novel coronavirus disease; and TNX-801, a potential smallpox and monkeypox vaccine; TNX-601 CR, a tianeptine oxalate controlled release tablet for the treatment of depressive disorder, posttraumatic stress disorder, and neurocognitive dysfunction from